Main > ONCOLOGY (**) > Kidney Cancer>RCC>MET *** > Treatment > USA. E. Cabozantinib ***

---

USA. E. Cabozantinib ***'s subsections
(*) CA Approval Date: 2018. 09.19.
(*) EU Approval Date: 2016. 09.09.>
(*) EU Approval Date: 2018. 05.17.>
(*) JP Approval Date: 2020. 03.
(*) USA Approval Date: 2016. 04.25>
(*) USA Approval Date: 2017. 12.20>
Company
Licensee (Ex JP & USA):
Licensee (JP):
Mechanism>Tyrosine Kinases Inh.>
Patent>Assignee; Claims; No.; Etc.
Patent>UpDate: 2016. 07.12.
RCC: Renal Cell Carcinoma
TradeMark
TradeMark Web-Site
UpDate: 2017. 01.30.

USA. E. Cabozantinib ***'s products
This section has no products